IMAC Holdings Receives FDA Authorization to Initiate Clinical Study of Its Umbilical Cord-Derived Allogenic Mesenchymal Stem Cells for the Treatment of Bradykinesia Due to Parkinson’s Disease

• NASDAQ: $IMAC
• Notified: $1.84
• 11:58 EDT